No Data
No Data
Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Prospects Need A Boost To Lift Shares
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 31x, you may consider Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) as an attractive investment with its
Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH) will distribute equity in the 2023 fiscal year at a rate of 0.20 yuan per share. The record date is June 14th.
Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) announced the implementation of its annual equity distribution plan for 2023. Based on the total share capital of the company before the implementation of the plan (excluding the shares in the company's repurchase account and the shares to be cancelled upon repurchase), a cash dividend of 0.20 yuan per share (including tax) will be distributed. The record date is June 14, 2024 and the ex-dividend date is June 17, 2024.
Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) CEO Hai Zhang, the Company's Largest Shareholder Sees 6.2% Reduction in Holdings Value
Key Insights Significant insider control over Guizhou Sanli PharmaceuticalLtd implies vested interests in company growth 52% of the business is held by the top 2 shareholders 17% of Guizhou Sanli
Guizhou Sanli (603439.SH): Currently, the OTC self-operated team is still under construction
Gelonghui, May 11丨Guizhou Sanli (603439.SH) said at the performance briefing that the company's OTC self-operated team is still under construction and will gradually increase the number of OTC team members in the future according to channel expansion and sales scale growth.
Guizhou Sanli (603439.SH) reported 2023 annual results, with net profit of 293 million yuan, an increase of 45.42% over the previous year
According to Zhitong Finance App, Guizhou Sanli (603439.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 1,635 billion yuan, an increase of 36.10%; net profit attributable to shareholders of listed companies was 293 million yuan, an increase of 45.42% year on year; net profit attributable to shareholders of listed companies deducted 246 million yuan from non-recurring profit and loss, an increase of 26.21% year on year; basic earnings per share were 0.71 yuan/share. The 2023 profit distribution plan proposed by the company is: the total share capital registered on the share registration date for implementing equity distribution (after deducting the company's special account for repurchase
Declining Stock and Solid Fundamentals: Is The Market Wrong About Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439)?
Guizhou Sanli PharmaceuticalLtd (SHSE:603439) has had a rough three months with its share price down 22%. But if you pay close attention, you might gather that its strong financials could mean that
No Data